Boston Scientific Corporation (BSX) is a leading medical devices business based in the US. It opened the day at $33.76 after a previous close of $34. During the day the price has varied from a low of $33.4327 to a high of $34.14. The latest price was $33.6 (25 minute delay). Boston Scientific is listed on the NYSE and employs 36,000 staff. All prices are listed in US Dollars.
Since the stock market crash in March caused by coronavirus, Boston Scientific's share price has had significant negative movement.
Its last market close was $37.77, which is 11.38% down on its pre-crash value of $42.62 and 56.72% up on the lowest point reached during the March crash when the shares fell as low as $24.1.
If you had bought $1,000 worth of Boston Scientific shares at the start of February 2020, those shares would have been worth $611.65 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $894.39.
|52-week range||$24.1 - $46.13|
|50-day moving average||$34.8553|
|200-day moving average||$37.1631|
|Wall St. target price||$43.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$2.605|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2021-01-15)||-7.51%|
|1 month (2020-12-22)||-2.21%|
|3 months (2020-10-22)||-8.84%|
|6 months (2020-07-22)||-12.48%|
|1 year (2020-01-22)||-23.72%|
|2 years (2019-01-22)||-9.82%|
|3 years (2018-01-22)||21.26%|
|5 years (2016-01-22)||88.24%|
Valuing Boston Scientific stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Boston Scientific's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Boston Scientific's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Boston Scientific shares trade at around 13x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Boston Scientific's P/E ratio is best considered in relation to those of others within the medical devices industry or those of similar companies.
Boston Scientific's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.7016. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Boston Scientific's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Boston Scientific's PEG ratio in relation to those of similar companies.
Boston Scientific's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $2.1 billion (£1.6 billion).
The EBITDA is a measure of a Boston Scientific's overall financial performance and is widely used to measure a its profitability.
To put Boston Scientific's EBITDA into context you can compare it against that of similar companies.
|Revenue TTM||$10.1 billion|
|Operating margin TTM||9.85%|
|Gross profit TTM||$7.6 billion|
|Return on assets TTM||2.16%|
|Return on equity TTM||29.32%|
|Market capitalisation||$49 billion|
TTM: trailing 12 months
There are currently 16.3 million Boston Scientific shares held short by investors – that's known as Boston Scientific's "short interest". This figure is 26.1% up from 13.0 million last month.
There are a few different ways that this level of interest in shorting Boston Scientific shares can be evaluated.
Boston Scientific's "short interest ratio" (SIR) is the quantity of Boston Scientific shares currently shorted divided by the average quantity of Boston Scientific shares traded daily (recently around 16.7 million). Boston Scientific's SIR currently stands at 0.98. In other words for every 100,000 Boston Scientific shares traded daily on the market, roughly 980 shares are currently held short.
To gain some more context, you can compare Boston Scientific's short interest ratio against those of similar companies.
However Boston Scientific's short interest can also be evaluated against the total number of Boston Scientific shares, or, against the total number of tradable Boston Scientific shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Boston Scientific's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Boston Scientific shares in existence, roughly 10 shares are currently held short) or 0.0116% of the tradable shares (for every 100,000 tradable Boston Scientific shares, roughly 12 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Boston Scientific.
Find out more about how you can short Boston Scientific stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Boston Scientific.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 29.23
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Boston Scientific's overall score of 29.23 (as at 01/01/2019) is nothing to write home about – landing it in it in the 57th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Boston Scientific is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
To gain some more context, you can compare Boston Scientific's total ESG risk score against those of similar companies.
Environmental score: 1.51/100
Social score: 12.87/100
Governance score: 7.87/100
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Boston Scientific scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Boston Scientific hasn't always managed to keep its nose clean.
Wondering how that compares? Below are the controversy scores of similar companies.
|Total ESG score||29.23|
|Total ESG percentile||56.94|
|Level of controversy||3|
We're not expecting Boston Scientific to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
You may also wish to consider:
Boston Scientific's shares were split on a 2:1 basis on 6 November 2003. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Boston Scientific shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Boston Scientific shares which in turn could have impacted Boston Scientific's share price.
Over the last 12 months, Boston Scientific's shares have ranged in value from as little as $24.1 up to $46.13. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Boston Scientific's is 0.8567. This would suggest that Boston Scientific's shares are less volatile than average (for this exchange).
To put Boston Scientific's beta into context you can compare it against those of similar companies.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.